Publicación:
Optimizing treatment to control LDL cholesterol using machine learning

Vista sencilla de ítem
dc.contributor.authorBoneu Yepez, Deiby
dc.contributor.authorSierra Porta, David
dc.contributor.authorMorales Aguas Liz
dc.contributor.authorManzur Jattin, Fernando
dc.contributor.researchgroupGrupo de Investigación Física Aplicada y Procesamiento de Imágenes y Señales- FAPIS
dc.date.accessioned2025-07-08T12:58:38Z
dc.date.issued2025
dc.description.abstractIncreased LDL cholesterol is one of the main risk factors for cardiovascular diseases; therefore, adequate therapy reduces the risk of developing cardiovascular disease. Artificial intelligence (AI) is a tool that can significantly help doctors select the optimal treatment aimed at each patient individually. Based on the above, the question arises: Which artificial intelligence model allows us to recommend the best treatment to control LDL levels according to the patient's cardiovascular risk factor?
dc.format.extent14 páginas
dc.format.mimetypeapplication/pdf
dc.identifier.citationYepez, D. B., Porta, D. S., Aguas, L. M., & Jattin, F. M. (2025). Optimizing treatment to control LDL cholesterol using machine learning. Computers In Biology And Medicine, 195, 110599. https://doi.org/10.1016/j.compbiomed.2025.110599
dc.identifier.doihttps://doi.org/10.1016/j.compbiomed.2025.110599
dc.identifier.urihttps://hdl.handle.net/20.500.12585/14096
dc.language.isoeng
dc.relation.referencesS. Yusuf et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study Lancet (2004)
dc.relation.referencesE. Galve et al. Grado de control lipídico en pacientes coronarios y medidas adoptadas por los médicos. Estudio REPAR Rev. Española Cardiol. (2016)
dc.relation.referencesJ. Pedro-Botet et al. Colesterol LDL, cuanto más bajo mejor Clín. Invest. Arterioscler. (2019)
dc.relation.referencesF.J. Raal et al. PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial Lancet (2015)
dc.relation.referencesJ.L. Speiser et al. A comparison of random forest variable selection methods for classification prediction modeling Expert Syst. Appl. (2019)
dc.relation.referencesN. Townsend et al. Cardiovascular disease in Europe: epidemiological update 2016 Eur. Heart J. (2016)
dc.relation.referencesB.A. Ference et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the european atherosclerosis society consensus panel Eur. Heart J. (2017)
dc.relation.referencesH. Tada et al. Comprehensive genotyping in dyslipidemia: mendelian dyslipidemias caused by rare variants and Mendelian randomization studies using common variants J. Hum. Genet. (2017)
dc.relation.referencesE.G. Díaz et al. Determinants of inertia with lipid-lowering treatment in patients with type 2 diabetes mellitus Endocrinología, Diabetes y Nutrición (English ed.) (2019)
dc.relation.referencesF. López-Simarro et al. The impact of therapeutic inertia and the degree of medication adherence on the control goals for patients with diabetes Semergen (2017)
dc.relation.referencesF.Y. Man et al. Therapeutic inertia in the management of hyperlipidaemia in type 2 diabetic patients: a cross-sectional study in the primary care setting Hong Kong Med. J. (2016)
dc.relation.referencesF. Mach et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: the task force for the management of dyslipidaemias of the European society of cardiology (ESC) and European atherosclerosis society (EAS) Eur. Heart J. (2020)
dc.subject.lembArtificial intelligence -- Medical applications
dc.subject.lembClinical decision support systems
dc.subject.lembMachine learning
dc.subject.lembPersonalized medicine
dc.subject.lembRenal cell carcinoma
dc.subject.lembClinical trials
dc.subject.lembTreatment adherence
dc.subject.lembHealth care -- Technological innovations
dc.subject.lembCardiovascular diseases
dc.subject.lembHypercholesterolemia -- Treatment
dc.subject.lembLow-density lipoproteins -- Therapeutic use
dc.subject.lembDyslipidemias -- Risk factors
dc.subject.lembAtherosclerosis -- Prevention and control
dc.subject.lembIschemic heart disease
dc.subject.lembTherapeutic inertia
dc.subject.lembDrug therapy -- Evaluation
dc.subject.lembEvidence-based medicine
dc.subject.proposalMachine learning
dc.subject.proposalLDL cholesterol
dc.subject.proposalHypolipidemic agents
dc.subject.proposalRisk factors
dc.titleOptimizing treatment to control LDL cholesterol using machine learning
dc.typeArtículo de revista
dc.type.contentText
dspace.entity.typePublication
relation.isAuthorOfPublication996a607a-3eb1-4484-8978-ed736b9fc0b7
relation.isAuthorOfPublication.latestForDiscovery996a607a-3eb1-4484-8978-ed736b9fc0b7

Archivos

Bloque original

Mostrando 1 - 1 de 1
Miniatura
Nombre:
1-s2.0-S0010482525009503-main copy.pdf
Tamaño:
4.76 MB
Formato:
Adobe Portable Document Format
Descargar

Bloque de licencias

Mostrando 1 - 1 de 1
Miniatura
Nombre:
license.txt
Tamaño:
14.49 KB
Formato:
Item-specific license agreed upon to submission
Descripción:
Descargar

Colecciones

Productos de investigación